https://www.nature.com/articles/s43586-021-00084-5  Abstract DNA-encoded chemical library (DECL) technology is used by the pharmaceutical industry to discover small molecules capable of modulating biologically relevant targets. DECL synthesis starts with an oligonucleotide that contains a chemical linker moiety, and proceeds through iterative cycles of DNA barcode elongation and chemical synthesis. DECL selections require little protein, minimal assay development …Read More >

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification in the drug discovery process. Fragments are small molecules with a low molecular weight, smaller than lead molecules or druglike molecules. The FBDD technology is based on identifying small chemical fragments, which bind to the biological target …Read More >

Challenging targets, such as membrane proteins or protein-protein interactions were considered undruggable in the past. However, today a variety of screening methods can be used to help develop drugs against these formerly undruggable targets.

Neurological disorders, such as neurodegenerative diseases, epilepsy, chronic pain, psychiatric disorders, are one of today’s largest unmet medical needs. However, due to poor disease and target understanding, Neuroscience drug discovery can be very challenging. An open access research platform with dedicated neuroscience specialists and integrated services will be an ideal partner throughout your drug discovery …Read More >

The CRISPR Cas9 System was first discovered as part of the bacterial adaptive immune response against viruses, but in recent years it’s revolutionized our techniques for genome editing. The Cas9 complex is formed of two components. A protein called Cas9 that can cut double stranded DNA, and a guide RNA, that binds to a specific …Read More >